Shareholder returns with priority given to investment in growth areas
First written in FY2016. 9 of 17 entries say "Restated". Latest entry: 2026-09-29.
- FY2026ReframedAnnual report
「Beginning with the fiscal year ending March 2027, we will shift shareholder returns from a model centered on dividends to a more flexible framework combining dividends with agile share repurchases.」
While maintaining the basic policy of prioritizing investment in growth drivers, the company changed shareholder returns from a dividend-centered model to a combination of dividends and agile share repurchases from FY2027 onward. - FY2025RestatedAnnual report
「To achieve sustainable growth for our Group, our policy is to allocate funds on a priority basis to investment in growth drivers, including investment in highly profitable existing businesses and strategic investment in growth opportunities. We will also provide proactive shareholder returns that take shareholder value into consideration while prioritizing investment in business growth and related areas.」
The company reconfirmed its capital allocation policy of prioritizing growth investment while providing shareholder returns through dividends and share repurchases. - FY2020RestatedAnnual report
「With regard to capital allocation to shareholders, there is no change to our longstanding policy. To achieve sustainable growth for our Group, we will prioritize investment in business growth and related areas while providing proactive shareholder returns that take shareholder value into consideration.」
The company reconfirmed that its capital allocation policy remains unchanged: prioritize growth investment while providing proactive shareholder returns. - FY2019RestatedAnnual report
「Our Group's basic policy for enhancing corporate value is to secure a stable financial foundation, prioritize investment in growth areas centered on the medical business, and provide ongoing shareholder returns.」
The company reconfirmed the priority order of its financial foundation, medical-focused growth investment, and ongoing shareholder returns. - FY2018RestatedAnnual report
「Our basic policy for enhancing corporate value is to secure a stable financial foundation, prioritize investment in growth areas centered on the medical business, and then provide shareholder returns after taking performance and other factors into consideration, in order to meet shareholder expectations.」
The company reconfirmed the priority order of its financial foundation, growth investment, and shareholder returns based on performance and other factors. - FY2017RestatedAnnual report
「Our basic policy for enhancing corporate value is to secure a stable financial foundation, prioritize investment in growth areas centered on the medical business, and then provide shareholder returns after taking performance and other factors into consideration.」
The company reconfirmed the priority order of its financial foundation, investment in growth areas, and shareholder returns based on performance and other factors. - FY2017-Q3RestatedAnnual report
「As one of the key strategies in the 2016 Corporate Strategic Plan announced on 30 March 2016 (hereinafter, “16CSP”), we set out the timely securing and maximum utilization of the management resources required, and are focusing the allocation of management resources on growth areas in the medical business.」
In explaining the reasons for selling non-core businesses, the company also reconfirmed its focus on allocating management resources to growth areas in the medical business. - FY2017-Q2RestatedAnnual report
「As one of the key strategies in the 2016 Corporate Strategic Plan announced on 30 March 2016 (hereinafter, “16CSP”), we set out the timely securing and maximum utilization of the management resources required, and are focusing the allocation of management resources on growth areas in the medical business.」
The company reconfirmed the focused allocation of management resources to growth areas in the medical business as a key strategy under 16CSP. - FY2016First statedAnnual report
「Our basic policy for enhancing corporate value is to secure a stable financial foundation, prioritize investment in growth areas centered on the medical business, and then provide shareholder returns after taking performance and other factors into consideration, in order to meet shareholder expectations.」
The company sets out the priority order of its financial foundation, growth investment, and shareholder returns.